Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial
Version 2 2024-06-04, 02:31Version 2 2024-06-04, 02:31
Version 1 2023-02-28, 00:20Version 1 2023-02-28, 00:20
journal contribution
posted on 2024-06-04, 02:31authored byA Granholm, MW Munch, SN Myatra, BKT Vijayaraghavan, M Cronhjort, RR Wahlin, SM Jakob, L Cioccari, MBN Kjær, GK Vesterlund, TS Meyhoff, M Helleberg, MH Møller, T Benfield, B Venkatesh, NE Hammond, S Micallef, A Bassi, O John, V Jha, KT Kristiansen, CS Ulrik, VL Jørgensen, M Smitt, MH Bestle, AS Andreasen, LM Poulsen, BS Rasmussen, AC Brøchner, T Strøm, A Møller, MS Khan, A Padmanaban, JV Divatia, S Saseedharan, K Borawake, F Kapadia, S Dixit, R Chawla, U Shukla, P Amin, MS Chew, CA Wamberg, C Gluud, T Lange, A Perner
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial